Auditory EEG and behavioral testing for people with Rett syndrome
Official title: Auditory EEG and Behavioral Assessments in Individuals With Rett Syndrome
Run by University of Rochester · NCT07569445 · Data updated 2026-11-12
This project will record noninvasive EEG while people with Rett syndrome and matched controls listen to simple sounds to see how their brains process sound.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 2 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | University of Rochester Academic / other |
| Locations | 1 site (Rochester, New York) |
| Status | Recruiting |
| Started | July 31, 2025 |
| Main results expected | August 2027 |
| Study ends | August 2027 |
| Registry record updated | May 6, 2026 |
| Trial ID | NCT07569445 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People aged 2 years or older with classic Rett syndrome and a confirmed pathogenic MECP2 variant who are past the regression stage, can tolerate noninvasive EEG, and whose parent or caregiver can provide permission and complete questionnaires are ideal candidates.
✕Probably not a fit
Individuals with hearing impairment, medical conditions that prevent safe EEG recording, inability to tolerate EEG procedures, or without a confirmed pathogenic MECP2 variant are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project records noninvasive EEG while participants with Rett syndrome and age/sex-matched controls listen to simple sounds through headphones. No active behavioral responses are required during the EEG, and parents or caregivers complete questionnaires and may be interviewed about symptoms, communication, daily functioning, and overall health. Clinicians or trained staff may complete a Rett syndrome severity scale, while control participants provide demographic information. The combined EEG and clinical data are collected to characterize auditory brain responses and related clinical features to support future biomarker and therapeutic research.
Why it matters
Potential benefit: If successful, this work could identify EEG signatures that help track or stratify Rett syndrome and guide future treatment development.
How similar studies have gone: Prior small studies have shown altered EEG and auditory responses in Rett syndrome, so this approach builds on promising but still preliminary biomarker work.
Who can join: the full rules
Show full inclusion / exclusion criteria
Rett Syndrome Participants: Inclusion Criteria: * Have a clinical diagnosis of classic Rett syndrome * Have a pathogenic MECP2 genetic variant confirmed via genetic testing * Are past the clinical regression stage * Are within the eligible age range for the study (2 years or older) * Are able to tolerate the noninvasive EEG recording * Parent or caregiver is willing and able to provide parental permission and complete questionnaires and interviews Exclusion Criteria: * Experiences hearing impairment or hearing loss * Presence of medical conditions that would prevent safe participation in EEG recording * Inability to tolerate EEG procedures * Any condition that in the opinion of the investigator would interfere with study participation or data quality Controls Inclusion Criteria: * Neurologically healthy individuals ages 2 years or older * Are able to tolerate the noninvasive EEG recording Exclusion Criteria: * Experiences hearing impairment or hearing loss * Medical history of genetic, neurological, or psychiatric disorders * History of special education services * Inability to tolerate EEG procedures * Any condition that in the opinion of the investigator would interfere with study participation or data quality
Where it's running
-
Center for Advanced Brain Imaging and Neurophysiology, University of Rochester Medical Center
Rochester, New York, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fenfluramine HCl for Rett Syndrome in a Phase 3 study
This study tests whether fenfluramine hydrochloride helps people with Rett syndrome when compared to a placebo.
-
Daily oral vorinostat for girls and young women with Rett syndrome
This trial will try daily oral vorinostat at two escalating dose levels, using a four-week placebo baseline and an N-of-1 design so each participant serves as her own control, to see if the drug is safe and shows clinical or molecular benefit in girls and young women with typical Rett syndrome.
-
Efficacy of Bionetide for treating Rett syndrome in females
This study is testing if an oral medication called Bionetide can help improve behavior and communication in girls and young women aged 5 to 20 with Rett syndrome.
-
Assessing cognitive function in Rett syndrome patients receiving trofinetide treatment
This study is testing how well eye-tracking tasks can measure cognitive abilities in people with Rett syndrome who are starting treatment with trofinetide.
-
Identifying biomarkers in Rett Syndrome
This study is trying to find specific brain signals in girls with Rett Syndrome to see how they differ from girls without the condition and how these signals relate to the severity of their symptoms over time.
-
Gene editing to correct common MECP2 mutations in Rett syndrome
This project will test CRISPR/Cas9 delivered with AAV to correct common MECP2 mutations in females with Rett syndrome using lab and animal work.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.